ONTAK
ONTAK is a pharmaceutical drug with 10 clinical trials. Historical success rate of 77.8%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
6
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
70.0%
7 of 10 finished
30.0%
3 ended early
0
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Vaccination Plus Ontak in Patients With Metastatic Melanoma
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Clinical Trials (10)
Vaccination Plus Ontak in Patients With Metastatic Melanoma
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10